{"id":"W2907407844","doi":"10.1634/theoncologist.2018-0838","title":"An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Weill Cornell Medical College; AstraZeneca; Genentech; Eli Lilly and Company; Agios Pharmaceuticals; Exelixis","keywords":"Medicine; Hepatocellular carcinoma; Cohort; Pharmacokinetics; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Toxicity; Gastroenterology; Phases of clinical research; Small interfering RNA; RNA","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007496428,0.000324944,0.0005859021,0.0001068641,0.000349383,0.00004018401,0.0003284612,0.00006345593,0.00002832472],"category_scores_gemma":[0.00004210244,0.0001722342,0.00002119459,0.0004031268,0.0004224489,0.0002134247,0.0002392281,0.0002195115,0.000002858895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001380647,"about_ca_system_score_gemma":0.0001629046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008967217,"about_ca_topic_score_gemma":0.0005608173,"domain_scores_codex":[0.9980378,0.0003796128,0.0003711181,0.0005349538,0.0003257481,0.0003508227],"domain_scores_gemma":[0.9985447,0.0001671765,0.0002345004,0.0006807623,0.0001872206,0.0001856342],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09249515,0.02461972,0.629335,0.00005030107,0.0001318307,0.0008310854,0.003732887,0.000004561045,0.1274365,0.000002102185,0.00001469017,0.1213462],"study_design_scores_gemma":[0.07414326,0.3416941,0.3750373,0.0002274291,0.001131834,0.0001996943,0.00116165,0.03586861,0.1700238,0.000003302312,0.0001282667,0.0003808177],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904872,0.0001640032,0.0001840344,0.000498727,0.00005955328,0.008426675,0.00003427762,0.00003602694,0.000109537],"genre_scores_gemma":[0.9983654,0.0000656095,0.0008818599,0.0001236316,0.00007289739,0.0003591849,0.00005374025,0.00004127965,0.00003641517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3170743,"threshold_uncertainty_score":0.7023508,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06688128871368598,"score_gpt":0.3491842452595836,"score_spread":0.2823029565458976,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}